Lymphocyte migration into brain modelled in vitro: Control by lymphocyte activation, cytokines, and antigen

doi:10.1016/0008-8749(90)90109-5

Cellular Immunology

Volume 127, Issue 1, 15 April 1990, Pages 1-11

https://doi.org/10.1016/0008-8749(90)90109-5 Get rights and content

Abstract

Factors controlling lymphocyte adhesion to brain endothelium were investigated in vitro. Mitogen activation of lymphocytes causes increased adhesion to endothelium, which is maximal at 7–24 hr, declines to normal levels after the cells divide, and requires protein synthesis. Rat brain endothelium can be stimulated with IFN-γ to increase its adhesion to either normal or activated lymphocytes. The endothelium is sensitive to low levels of cytokine: adhesion develops rapidly after stimulation and requires new protein synthesis. Antigen-specific line cells also adhere more effectively to endothelium than normal lymph node cells. This is enhanced by IFN-γ treatment of the endothelium and is further increased marginally in the presence of the cognate antigen. The results suggest that either local stimulation of endothelium with cytokines or lymphocyte activation in the periphery will modulate lymphocyte traffic into brain.

References (21)

U. Traugott et al.
Science
(1983)
Y. Matsumoto et al.
J. Immunol
(1986)
C.C.W. Hughes et al.
Immunology
(1988)
T.B. Issekutz et al.
Immunology
(1986)
M.L. Dustin et al.
J. Immunol
(1986)
T. Springer et al.
Annu. Rev. Immunol
(1987)
T. Collins et al.
J. Immunol
(1984)
J.S. Pober et al.
J. Immunol
(1986)
D.E. Cavender et al.
J. Immunol
(1986)
C.C.W. Hughes et al.
Neurosci. Lett
(1986)

There are more references available in the full text version of this article.

Cited by (111)

Hypothalamitis and pituitary atrophy
2021, Handbook of Clinical Neurology
Citation Excerpt :
Cultured glial, but not neuronal cells are able to express HLA class II molecules that can present antigens in vitro (Fontana et al., 1984). A further immunological protection of the brain is provided by the fact that lymphocytes are much less adhesive for brain microvessel endothelium than extracerebral endothelium, but adhesion can be increased by stimulation of endothelial cells with interferon gamma or tumor necrosis factor-alpha (Male et al., 1990a). Mitogen-activated lymphocytes or T cells activated by their specific antigen bind more effectively than resting lymphocytes (Male et al., 1990b).
Hypothalamitis is a rare inflammatory disorder involving the hypothalamus and classified as primary, or isolated, and secondary hypothalamitis. Secondary hypothalamitis although very rare is more common than the primary one and may occur in patients affected by autoimmune diseases such as autoimmune hypophysitis, systemic autoimmune diseases, infective diseases in patients affected by immune-deficit, paraneoplastic encephalitis, or in patients treated with immune checkpoint inhibitors. In accordance with the rarity of this disease, diagnosis and management of hypothalamitis prove to be challenging. The diagnosis requires a high index of clinical suspicion. The main symptoms may be: various degrees of hypopituitarism, neuropsychiatric and behavioral disorders, and disturbances of autonomic and metabolic regulation. Magnetic resonance images play a crucial role in the diagnosis of hypothalamitis and in the exclusion of a neoplastic lesion. Therapeutic management should be oriented according to the disease etiology. In most cases, after ruling out infective hypothalamitis, the mainstay of therapy consists of immunosuppressive treatment. Great attention should be paid to hormonal replacement therapy, if partial or total hypopituitarism is present, in particular in patients affected by diabetes insipidus, central hypoadrenalism and hypothyroidism. According to the complexity of this disease, a multidisciplinary approach is strongly advocated to reach an early diagnosis and an integrated therapy.
Injection of the sciatic nerve with TMEV: A new model for peripheral nerve demyelination
2007, Virology
Citation Excerpt :
These results indicated that the adaptive immune response plays a critical role in protection of mice inoculated with TMEV via the sciatic nerve. Inflammatory cells are not detected in normal PNS or CNS (Male et al., 1992; Male et al., 1990a,b; Wekerle et al., 1986) but damage to either the PNS or CNS can culminate in the recruitment of inflammatory and/or immune cells to the site of injury (Male et al., 1990a, 1992). Lymphocytic infiltration of the brain in the TMEV model of CNS demyelination is apparent by 3–5 days p.i. (Lindsay and Rodriguez, 1989; Lindsley et al., 1988); the tissue is infiltrated by T and B cells as well as macrophages (Lindsley et al., 1988).
Demyelination of the human peripheral nervous system (PNS) can be caused by diverse mechanisms including viral infection. Despite association of several viruses with the development of peripheral demyelination, animal models of the condition have been limited to disease that is either autoimmune or genetic in origin. We describe here a model of PNS demyelination based on direct injection of sciatic nerves of mice with the cardiovirus, Theiler's murine encephalomyelitis virus (TMEV). Sciatic nerves of FVB mice develop inflammatory cell infiltration following TMEV injection. Schwann cells and macrophages are infected with TMEV. Viral replication is observed initially in the sciatic nerves and subsequently the spinal cord. Sciatic nerves are demyelinated by day 5 post-inoculation (p.i.). Injecting sciatic nerves of scid mice resulted in increased levels of virus recovered from the sciatic nerve and spinal cord relative to FVB mice. Demyelination also occurred in scid mice and by 12 days p.i., hindlimbs were paralyzed. This new model of virus-induced peripheral demyelination may be used to dissect processes involved in protection of the PNS from viral insult and to study the early phases of lesion development.
Rhesus macaque brain microvessel endothelial cells behave in a manner phenotypically distinct from umbilical vein endothelial cells
2001, Journal of Neuroimmunology
Activation of endothelium is a critical step in leukocyte recruitment to the CNS and in development of neurological diseases, such as HIV-associated dementia. Due to limited availability of early disease course data, it is important to develop in vitro models of the blood–brain barrier (BBB) that can be used to address these early events. No such model of the BBB has been established for the macaque. Here, we characterize rhesus microvascular brain endothelial cells (MBEC), comparing them with rhesus umbilical vein endothelial cells (RUVEC), and discuss their suitability for future use in developing in vitro models of simian immunodeficiency virus (SIV) neuropathogenesis. We conclude that MBEC are distinct from RUVEC with respect to growth characteristics, culture requirements, morphology and expression of surface molecules important for leukocyte adhesion and immune activation.
Amelioration of CR-EAE with lisofylline: Effects on mRNA levels of IL-12 and IFN-γ in the CNS
2000, Journal of Neuroimmunology
CR-EAE is a Th1-mediated inflammatory autoimmune demyelinating disease of the CNS and serves as a model of human multiple sclerosis. Our previous studies have shown the protective effect of orally administered lisofylline in the prevention of active and passively induced acute EAE. In our present studies we have examined the efficacy and mechanism of action of lisofylline on CR-EAE. Lisofylline decreased the number and severity of paralytic attacks in mice with relapsing EAE. The reduction of clinical disease correlated with decreased levels of mRNA levels of IFN-γ but not of mRNA levels of IL-12. These studies suggest that lisofylline may be an effective therapeutic for established Th1 mediated autoimmune disease and that it acts by blocking IL-12R signaling and not IL-12 production in vivo.
Serum endothelial adhesion molecules levels correlate with lesion burden in multiple sclerosis patients treated with interferon beta-1b
2000, Neurochemistry International
The levels of serum-soluble intracellular adhesion molecule-1 and soluble endothelial-leukocyte adhesion molecule-1, and the Gadolinium-enhanced T1-weighted MRI were studied in a group of patients with relapsing–remitting multiple sclerosis treated with interferon beta-1b and compared to a non-treated control group. The levels of serum-soluble intracellular adhesion molecule-1 and soluble endothelial-leukocyte adhesion molecule-1 increased, after three months treatment, as compared to baseline and the non-treated MS patients. A significant correlation was found in the treated group between serum-soluble endothelial-leukocyte adhesion molecule-1 and the lesion area in the Gadolinium-enhancing (T2 weighted scan) MRI.
Temporal kinetics and cellular phenotype of TNF p55/p75 receptors in experimental allergic encephalomyelitis
1999, Journal of Neuroimmunology
TNF-α and LT-α are thought to be involved in the immunopathology of CNS demyelinating diseases. Both cytokines induce cellular effects through 55-kDa type-1 receptors (R1) and 75-kDa type-2 receptors (R2). To date, no study has specifically identified the various cell populations that express TNF receptors (TNFR) in the inflammatory and demyelinating mouse model, EAE. Phenotyping the TNFR positive cells is important in determining when and where the ligands may be acting and playing a role in disease pathology. We observed an upregulation of TNF R1 and R2 mRNA in high endothelial venules (HEVs) in the lymph node and CNS before the onset of EAE (preclinical phase). This upregulation of TNFR expression in HEVs was followed by a rapid increase in leukocytes within the CNS after the onset of clinical disease. The temporal kinetics of these data suggest that HEVs become activated early, probably through the release of pro-inflammatory cytokines originating from circulating leukocytes. An increase in TNFR on HEVs would make these cells more susceptible to TNF-induced changes, such as increasing cellular adhesion molecules, thereby further facilitating the trafficking of leukocytes into the CNS parenchyma.

View all citing articles on Scopus

^☆: This work was supported by grants from the Medical Research Council of Great Britain and the Wellcome Trust.

View full text

Lymphocyte migration into brain modelled in vitro: Control by lymphocyte activation, cytokines, and antigen☆

Abstract

Science

J. Immunol

Immunology

Immunology

J. Immunol

Annu. Rev. Immunol

J. Immunol

J. Immunol

J. Immunol

Neurosci. Lett